TATAA Biocenter partners with Olink to add high quality proteomics with unrivaled throughput to their multi-omics offering

3/9/2022, 2:00 PM (Source: GlobeNewswire)

UPPSALA, Sweden, March 09, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced its collaboration with TATAA Biocenter, a leading European provider of molecular analysis services, launching Olink® Explore 3072 proteome profiling service.

“Olink® Explore is a perfect platform to complement our already optimized genomics and transcriptomics offerings and will be imperative in our services supporting the pharmaceutical industry,” said Mikael Kubista, founder, and CEO of TATAA Biocenter. “We already offer workflow optimizations and validations including multiomics, and with this new platform our capacity dramatically increases. TATAA Biocenter will also use the Olink technology for proteomics analysis in the European Union-funded projects identifying molecular mechanisms of pain related disorders (PainFACT) and “Combining optoacoustic imaging phenotypes and multi-omics to advance diabetes healthcare” (OPTOMICS).”

The Olink market-leading proteomics solution measures up to 3,000 proteins per sample using Proximity Extension Assay (PEA) technology combined with next generation (NGS) sequencing readout on the Illumina® NovaSeq and Illumina® NextSeq platforms providing a highly sensitive and reproducible multiplexed method with exceptional specificity. 

“In heart failure, my area of interest, it is very common that we don’t know for sure how drugs work. Biomarker research, optimally using proteomics, such as enabled by Olink® Explore 3072, when applied to clinical trial blood samples and with appropriate use of sophisticated data science, may help unravel the mechanisms of action (MOA) of therapies, “said professor Faiez Zannad, Head of the Centre d’Investigation Clinique Pierre Drouin Inserm, coordinator of the HOMAGE (Heart OMics in AGEing) project one of the speakers at the Olink® Explore launch event at TATAA Biocenter in Gothenburg, Sweden. “For example, in the HOMAGE trial (Heart Omics in AGEing project), I was amazed by being able to describe the multiple MOAs of the mineralocorticoid receptor antagonist spironolactone, mostly known, so far, only from animal experimental data. Examining the MOAs of drugs in the clinical setting is among the major advances allowed by proteomics.”

TATAA Biocenter has more than 20 years’ experience serving the pharmaceutical and diagnostic industries and the research community with genomics, transcriptomics, and proteomics services. Focusing on cell and gene therapies, TATAA Biocenter’s platforms such as the Olink® Explore 3072 and proprietary technologies like 2-tailed PCR offer important performance advantages.

“We are excited to be partnering with TATAA Biocenter. This will make the Olink proteomics platform more accessible to the scientific community, which is in line with our mission of accelerating research in areas such as the understanding of disease, more efficient and safer drug development, and enablement of earlier and more accurate diagnoses, said Henk Mouthaan, Vice President Sales and Marketing EMEA, Olink Proteomics.

IR Contact
Jan Medina, CFA, VP Investor Relations & Capital Markets, Olink
Mobile: +1 617 802 41

Media Contact
Andrea Prander, Corporate Communications Manager, Olink
Mobile: +46 768 775 275

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

About TATAA Biocenter
TATAA Biocenter is leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industry in Europe and the Cell and Gene Therapy in the United States. With ISO 17025 accreditation and Good Laboratory and Clinical Practices (GLP/GCP) TATAA is perfectly positioned to support the pharmaceutical industry with biomarker profiling including genomics, transcriptomics, and proteomics with traditional qPCR, dPCR and NGS methods as well as proprietary methods.www.tataa.com

Forward-Looking Statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.